PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
0.49%
Gross profit growth of 0.49% while RVPH is zero. Bruce Berkowitz would see if minimal improvements could expand further.
56.85%
EBIT growth above 1.5x RVPH's 5.85%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
54.90%
Operating income growth above 1.5x RVPH's 7.11%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
56.85%
Net income growth above 1.5x RVPH's 5.90%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
56.86%
EPS growth above 1.5x RVPH's 7.69%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
56.86%
Diluted EPS growth above 1.5x RVPH's 7.69%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.00%
Share reduction while RVPH is at 2.47%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while RVPH is at 2.47%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
28.81%
OCF growth at 50-75% of RVPH's 38.83%. Martin Whitman would question if the firm lags in monetizing sales effectively.
28.81%
FCF growth 50-75% of RVPH's 38.83%. Martin Whitman would see if structural disadvantages exist in generating free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while RVPH stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
95.99%
OCF/share CAGR of 95.99% while RVPH is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
56.40%
5Y OCF/share CAGR above 1.5x RVPH's 21.52%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-114.69%
Negative 3Y OCF/share CAGR while RVPH stands at 53.59%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
96.39%
Positive 10Y CAGR while RVPH is negative. John Neff might see a substantial advantage in bottom-line trajectory.
45.76%
5Y net income/share CAGR at 75-90% of RVPH's 60.51%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
32.63%
3Y net income/share CAGR 50-75% of RVPH's 58.01%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
-96.80%
Negative equity/share CAGR over 10 years while RVPH stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-86.34%
Negative 5Y equity/share growth while RVPH is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-81.50%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.20%
Negative asset growth while RVPH invests at 64.40%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-26.00%
We have a declining book value while RVPH shows 89.95%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-9.98%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-36.64%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-70.64%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.